Outcomes in COVID-19 nigella sativa studies
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Tau2 = 0.00, I2 = 0.0%, p = 0.0013
Early treatment 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement Al-Haidari 62%
0.38 [0.31-0.46]
symp. case
68/188
180/188
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p < 0.0001
Prophylaxis 62%
0.38 [0.31-0.46]
68/188
180/188
62% improvement All studies 67%
0.33 [0.21-0.52]
71/596
209/695
67% improvement 4 nigella sativa COVID-19 studies c19ns.com Jan 19, 2022
Tau2 = 0.06, I2 = 10.1%, p < 0.0001
Effect extraction pre-specified
1 CT: study uses combined treatment Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
0/160
14/259
Tau2 = 0.00, I2 = 0.0%, p = 0.0026
Early treatment 87%
0.13 [0.04-0.49]
2/317
25/415
87% improvement All studies 87%
0.13 [0.04-0.49]
2/317
25/415
87% improvement 2 nigella sativa COVID-19 mortality results c19ns.com Jan 19, 2022
Tau2 = 0.00, I2 = 0.0%, p = 0.0026
1 CT: study uses combined treatment Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p = 0.22
Early treatment 75%
0.25 [0.03-2.22]
1/91
4/92
75% improvement All studies 75%
0.25 [0.03-2.22]
1/91
4/92
75% improvement 1 nigella sativa COVID-19 hospitalization result c19ns.com Jan 19, 2022
Tau2 = 0.00, I2 = 0.0%, p = 0.22
Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Tau2 = 0.00, I2 = 0.0%, p = 0.0013
Early treatment 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement All studies 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement 3 nigella sativa COVID-19 serious outcomes c19ns.com Jan 19, 2022
Tau2 = 0.00, I2 = 0.0%, p = 0.0013
Effect extraction pre-specified
1 CT: study uses combined treatment Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 84%
0.16 [0.11-0.24]
no recov.
107 (n)
103 (n)
CT1
Improvement, RR [CI] Treatment Control Koshak (RCT) 43%
0.57 [0.42-0.78]
no recov.
34/91
60/92
Tau2 = 0.76, I2 = 96.2%, p = 0.059
Early treatment 69%
0.31 [0.09-1.05]
34/198
60/195
69% improvement All studies 69%
0.31 [0.09-1.05]
34/198
60/195
69% improvement 2 nigella sativa COVID-19 recovery results c19ns.com Jan 19, 2022
Tau2 = 0.76, I2 = 96.2%, p = 0.059
1 CT: study uses combined treatment Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Al-Haidari 62%
0.38 [0.31-0.46]
symp. case
68/188
180/188
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p < 0.0001
Prophylaxis 62%
0.38 [0.31-0.46]
68/188
180/188
62% improvement All studies 62%
0.38 [0.31-0.46]
68/188
180/188
62% improvement 1 nigella sativa COVID-19 case result c19ns.com Jan 19, 2022
Tau2 = 0.00, I2 = 0.0%, p < 0.0001
Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.12-0.27]
viral+
107 (n)
103 (n)
CT1
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p < 0.0001
Early treatment 82%
0.18 [0.12-0.27]
0/107
0/103
82% improvement All studies 82%
0.18 [0.12-0.27]
0/107
0/103
82% improvement 1 nigella sativa COVID-19 viral clearance result c19ns.com Jan 19, 2022
Tau2 = 0.00, I2 = 0.0%, p < 0.0001
1 CT: study uses combined treatment Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Tau2 = 0.00, I2 = 0.0%, p = 0.0013
Early treatment 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement All studies 84%
0.16 [0.05-0.48]
3/408
29/507
84% improvement 3 nigella sativa COVID-19 Randomized Controlled Trials c19ns.com Jan 19, 2022
Tau2 = 0.00, I2 = 0.0%, p = 0.0013
Effect extraction pre-specified
1 CT: study uses combined treatment Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
0/160
14/259
Tau2 = 0.00, I2 = 0.0%, p = 0.0026
Early treatment 87%
0.13 [0.04-0.49]
2/317
25/415
87% improvement All studies 87%
0.13 [0.04-0.49]
2/317
25/415
87% improvement 2 nigella sativa COVID-19 RCT mortality results c19ns.com Jan 19, 2022
Tau2 = 0.00, I2 = 0.0%, p = 0.0026
1 CT: study uses combined treatment Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Improvement, RR [CI] Treatment Control Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Tau2 = 0.00, I2 = 0.0%, p = 0.02
Early treatment 87%
0.13 [0.02-0.72]
1/251
18/351
87% improvement Al-Haidari 62%
0.38 [0.31-0.46]
symp. case
68/188
180/188
Improvement, RR [CI] Treatment Control Tau2 = 0.00, I2 = 0.0%, p < 0.0001
Prophylaxis 62%
0.38 [0.31-0.46]
68/188
180/188
62% improvement All studies 69%
0.31 [0.15-0.67]
69/439
198/539
69% improvement 3 nigella sativa COVID-19 peer reviewed trials c19ns.com Jan 19, 2022
Tau2 = 0.17, I2 = 18.1%, p = 0.0027
Effect extraction pre-specified
Favors nigella sativa
Favors control
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Ashraf (RCT) 82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI] Treatment Control Ashraf (RCT) 67%
0.33 [0.01-7.99]
death
0/107
1/103
CT1
Ashraf (RCT) 79%
0.21 [0.05-0.92]
death
2/50
10/53
CT1
Ashraf (RCT) 84%
0.16 [0.11-0.24]
no recov.
107 (n)
103 (n)
CT1
Ashraf (RCT) 75%
0.25 [0.15-0.41]
no recov.
50 (n)
53 (n)
CT1
Ashraf (RCT) 82%
0.18 [0.12-0.27]
viral+
107 (n)
103 (n)
CT1
Ashraf (RCT) 77%
0.23 [0.14-0.38]
viral+
50 (n)
53 (n)
CT1
Al-Haidari (RCT) 96%
0.04 [0.00-0.70]
death
0/160
14/259
Al-Haidari (RCT) 93%
0.07 [0.02-0.30]
severe case
2/160
44/259
Koshak (RCT) 75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Koshak (RCT) 43%
0.57 [0.42-0.78]
no recov.
34/91
60/92
Al-Haidari 62%
0.38 [0.31-0.46]
symp. case
68/188
180/188
nigella sativa COVID-19 outcomes c19ns.com Jan 19, 2022
1 CT: study uses combined treatment Favors nigella sativa
Favors control
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
WCH
and
FLCCC provide
treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.
Submit
